Translational Development Acquisition (TDACW) Net Cash Flow (2024 - 2026)

Translational Development Acquisition (TDACW) has reported Net Cash Flow for 3 consecutive years, with -$27.6 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Net Cash Flow fell 15982.28% year-over-year to -$27.6 million; the trailing twelve-month figure through Jun 2026 stood at -$27.7 million (down 115.88% YoY), and the FY2025 full-year result was -$408387.0, down 193.63% from the prior year.
• Net Cash Flow slipped to -$27.6 million in Q2 2026 per TDACW's latest filing, from -$5157.0 in the prior quarter.
• Across five years, Net Cash Flow topped out at $174.4 million in Q4 2024 and bottomed at -$27.6 million in Q2 2026.
• Historically, Net Cash Flow has averaged $18.3 million across 3 years, with a median of -$52734.0 in 2025.
• The widest YoY moves for Net Cash Flow: up 97.77% in 2026, down 15982.28% in 2026.
• Over 3 years, Net Cash Flow stood at $174.4 million in 2024, then slumped by 100.01% to -$17363.0 in 2025, then slumped by 158606.37% to -$27.6 million in 2026.
• According to Business Quant data, Net Cash Flow over the past three periods registered -$27.6 million, -$5157.0, and -$17363.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.